The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.

Inclusion Criteria:

• Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)
• Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
• Subject has been prescribed ADVATE by their treating physician
• Subject may be of any age
• Subject or parent/legally authorized representative has provided written informed consent

Exclusion Criteria:

• None